MX2015011386A - Metodo para tratar cancer pancreatico. - Google Patents
Metodo para tratar cancer pancreatico.Info
- Publication number
- MX2015011386A MX2015011386A MX2015011386A MX2015011386A MX2015011386A MX 2015011386 A MX2015011386 A MX 2015011386A MX 2015011386 A MX2015011386 A MX 2015011386A MX 2015011386 A MX2015011386 A MX 2015011386A MX 2015011386 A MX2015011386 A MX 2015011386A
- Authority
- MX
- Mexico
- Prior art keywords
- pancreatic cancer
- treat pancreatic
- notch
- levels
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361794788P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/026094 WO2014151606A2 (en) | 2013-03-15 | 2014-03-13 | Methods of treating pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015011386A true MX2015011386A (es) | 2016-02-03 |
Family
ID=51581651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011386A MX2015011386A (es) | 2013-03-15 | 2014-03-13 | Metodo para tratar cancer pancreatico. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160030561A1 (https=) |
| EP (1) | EP2971146A4 (https=) |
| JP (1) | JP2016520289A (https=) |
| KR (1) | KR20150130466A (https=) |
| CN (1) | CN105051215A (https=) |
| AU (1) | AU2014233736A1 (https=) |
| CA (1) | CA2900969A1 (https=) |
| HK (1) | HK1211322A1 (https=) |
| IL (1) | IL240688A0 (https=) |
| MX (1) | MX2015011386A (https=) |
| WO (1) | WO2014151606A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7919092B2 (en) | 2006-06-13 | 2011-04-05 | Oncomed Pharmaceuticals, Inc. | Antibodies to notch receptors |
| EP2125887A4 (en) | 2007-01-24 | 2010-11-10 | Oncomed Pharm Inc | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| CN104402998A (zh) | 2008-07-08 | 2015-03-11 | 昂考梅德药品有限公司 | 分离的抗体 |
| US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| US9944700B2 (en) | 2013-03-13 | 2018-04-17 | Novartis Ag | Notch2 binding molecules for treating respiratory diseases |
| US20190309369A1 (en) * | 2016-05-09 | 2019-10-10 | Inserm (Institute National De La Sante Et De La Recherche Medicale) | Methods for classifying patients with a solid cancer |
| EP3595717A1 (en) * | 2017-03-17 | 2020-01-22 | Imclone, LLC | Combination therapy for pancreatic cancer |
| KR20200005540A (ko) * | 2017-04-14 | 2020-01-15 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
| WO2019203255A1 (ja) * | 2018-04-19 | 2019-10-24 | 公立大学法人横浜市立大学 | 再構成癌組織を用いた薬剤評価方法 |
| WO2023225345A1 (en) * | 2022-05-20 | 2023-11-23 | Mayo Foundation For Medical Education And Research | Treating chemoresistant cancers with notch3 inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040102390A1 (en) * | 2002-11-21 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of Notch3 expression |
| WO2005111072A2 (en) * | 2004-04-29 | 2005-11-24 | The Trustees Of Columbia University In The City Of New York | Notch-based fusion proteins and uses thereof |
| US7807630B2 (en) * | 2007-09-14 | 2010-10-05 | Vanderbilt University | Targeting of Notch3 receptor function for cancer therapy |
| CN104402998A (zh) * | 2008-07-08 | 2015-03-11 | 昂考梅德药品有限公司 | 分离的抗体 |
| US9062311B2 (en) * | 2009-01-26 | 2015-06-23 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Means and methods for modulating NOTCH3 protein expression and/or the coding region of NOTCH3; compositions and use thereof in the treatment of CADASIL |
| CA2775880A1 (en) * | 2009-09-30 | 2011-04-07 | Genentech, Inc. | Anti-notch3 antagonist antibodies to treat gamma secretase inhibitor responsive and anti-notch1 antagonist antibody unresponsive t-cell leukemias |
-
2014
- 2014-03-13 JP JP2016502049A patent/JP2016520289A/ja not_active Withdrawn
- 2014-03-13 CA CA2900969A patent/CA2900969A1/en not_active Abandoned
- 2014-03-13 MX MX2015011386A patent/MX2015011386A/es unknown
- 2014-03-13 KR KR1020157028505A patent/KR20150130466A/ko not_active Withdrawn
- 2014-03-13 EP EP14768242.1A patent/EP2971146A4/en not_active Withdrawn
- 2014-03-13 US US14/776,259 patent/US20160030561A1/en not_active Abandoned
- 2014-03-13 AU AU2014233736A patent/AU2014233736A1/en not_active Abandoned
- 2014-03-13 CN CN201480016155.2A patent/CN105051215A/zh active Pending
- 2014-03-13 WO PCT/US2014/026094 patent/WO2014151606A2/en not_active Ceased
- 2014-03-13 HK HK15112123.8A patent/HK1211322A1/xx unknown
-
2015
- 2015-08-20 IL IL240688A patent/IL240688A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014151606A2 (en) | 2014-09-25 |
| US20160030561A1 (en) | 2016-02-04 |
| HK1211322A1 (en) | 2016-05-20 |
| CA2900969A1 (en) | 2014-09-25 |
| WO2014151606A3 (en) | 2014-11-27 |
| EP2971146A4 (en) | 2016-11-09 |
| EP2971146A2 (en) | 2016-01-20 |
| AU2014233736A1 (en) | 2015-08-27 |
| CN105051215A (zh) | 2015-11-11 |
| JP2016520289A (ja) | 2016-07-14 |
| WO2014151606A4 (en) | 2015-01-29 |
| KR20150130466A (ko) | 2015-11-23 |
| IL240688A0 (en) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015011386A (es) | Metodo para tratar cancer pancreatico. | |
| CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
| MX2016005294A (es) | Metodos para tratar y prevenir enfermedad injerto contra huésped. | |
| MX2016000271A (es) | Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r. | |
| GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
| CL2015003280A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
| CL2016000055A1 (es) | Métodos para tratar o prevenir afecciones oftalmológicas | |
| MX2016013457A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| EA201690549A1 (ru) | Арилэфиры и их применения | |
| MX2017016868A (es) | Composiciones y metods para inhibir actividad de arginasa. | |
| EA201591543A1 (ru) | Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| MX379297B (es) | Compuestos alqueno tetrasustituidos y su uso. | |
| MX370664B (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| CL2015002807A1 (es) | Terapia de combinación | |
| MX359227B (es) | Tratamiento de cáncer con inhibidores de tor cinasa. | |
| NI201400112A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| DOP2019000019A (es) | Metodos para tratar el cancer de prostata | |
| MX2016006955A (es) | Metodos para tratar y evitar enfermedad cronica de injerto versus anfitrion impulsada por aloanticuerpo. | |
| NI201500151A (es) | Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata. | |
| NI201500063A (es) | Tratamiento de cáncer con pomalidomida en un individuo con daño renal | |
| NI201500055A (es) | Tratamiento de cáncer de próstata con inhibidores de quinasa tor | |
| MX2017010002A (es) | Terapias de combinacion. | |
| MX2017011018A (es) | Inhibicion de la actividad de olig2. |